Brought to you by 
Bayer buys cell therapy investment BlueRock for up to $600mm
26 Aug 2020
Executive Summary
Bayer AG fully acquired privately held cell therapeutics developer BlueRock Therapeutics, paying $240mm in cash up front for 59.2% of the company it did not already own, and pledging another $360mm in development milestones. Including Bayer’s previous investment, BlueRock is valued at $1bn.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer buys cell therapy investment BlueRock for up to $600mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice